Aims Clinical trials have reported conflicting results about whether celecoxib plus
chemotherapy improves outcomes over chemotherapy alone in patients with advanced non …

Background The clinical benefit of a selective cyclooxygenase-2 inhibitor, celecoxib,
combined with anticancer therapy in advanced non-small-cell lung cancer (NSCLC) remains …

Background: Studies have reported that advanced NSCLC benefits from celecoxib
combined with systematic treatment. However, the optimal combination with different …

Background Increased expression of cyclooxygenase-2 (COX-2) is common in non-small
cell lung cancer (NSCLC) and has been associated with poor prognosis. Experimental and …

Abstract Aim: Inhibition of cyclooxygenase-2 (COX-2) is proposed as a treatment option in
several cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have …

Background and objective Currently, platinum-based regimes are standard first-line
chemotherapy for non-small cell lung cancer. The aim of this study is to evaluate the efficacy …

Introduction To evaluate the efficacy and toxicity of the combination of celecoxib and
docetaxel in patients with advanced non-small cell lung cancer after failure of platinum …

8005 Background: Cox-2 is overexpressed in NSCLC tumors and has a negative impact on
survival. It is involved in proliferation and angiogenesis. The hypothesis is that celecoxib by …

PURPOSE The selection of effective schedules of treatment for metastatic non-small cell
lung cancer still remains a challenge for the oncologist. The present multicentric phase II …

Purpose Cyclooxygenase-2 (COX-2) protein expression in patients with non–small-cell lung
cancer (NSCLC) may be not only a prognostic marker but also predictive for COX-2 …